- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07945652
Portable Absence Seizure Detection Using Smart Earbuds (PAUSE)
Typical absence seizures are the hallmark of idiopathic generalized epilepsy syndromes (CAE, JAE, JME) but are frequently underreported in patient diaries. Clinical studies have shown that 74% to 94% of absence seizures go unreported by patients or caregivers. While 24-hour video-EEG (vEEG) is the gold standard for quantification, it is expensive, hospital-based, and lacks the temporal resolution required for long-term management.
Previous studies successfully validated a wearable EEG (wEEG) solution using a behind-the-ear (BTE) form factor (Byteflies Sensor Dot). In the pilot study, the authors demonstrated that a reduced electrode configuration combined with ML algorithms could detect absence seizures with 98% sensitivity in the hospital setting and enable effective home-based treatment monitoring.
To expand the applicability of this method, validation of additional form factors is required. This study aims to extend our validation framework to a novel wEEG device that utilizes an ear configuration (earEEG).
Přehled studie
Postavení
Detailní popis
-
Background, rationale and risk assessment
1.1 Disease Background Typical absence seizures are the clinical hallmark of idiopathic generalized epilepsy syndromes, specifically Childhood Absence Epilepsy (CAE), Juvenile Absence Epilepsy (JAE), and Juvenile Myoclonic Epilepsy (JME)(1). These syndromes account for up to 20% of all people living with epilepsy, primarily affecting children, adolescents, and young adults(2). Clinically, absences are characterized by a transient loss of consciousness accompanied by generalized 3 Hz (2.5-5.5 Hz) spike-and-wave discharges (SWD) on the electroencephalogram (EEG). These seizures can have significant cognitive, affective, and behavioral comorbidities, particularly when not adequately controlled(1,3-5).
1.2 Limitations of the Current Standard of Care Accurate quantification of the seizure burden is essential for optimizing the treatment with anti-seizure medications (ASM). The current standard of care relies on seizure diaries. However, previous studies indicate that the sensitivity of self-reporting for absence seizures ranges from 6% to 26% compared with video-EEG(6,7). i.e., seizure diaries have low reliability.
Therefore, patients are intermittently followed with a 24-hour video electroencephalogram (vEEG), which has, among other limitations, high costs (approximately €1,200 per session in Belgium), long waiting times, and limited ecological validity, as they provide only a snapshot of the patient's condition that may not capture cyclical seizure variability(8).
This study seeks to validate an objective, automated counting method using a wearable EEG (wEEG) device, first in a hospital setting and then at home.
1.3 Rationale for Wearable EEG wEEG devices offer a promising alternative to full-scalp vEEG for long-term monitoring. By using a limited number of electrodes combined with Machine Learning (ML) algorithms, wEEG can enable intermittent or continuous, objective seizure counting outside the hospital.
Researchers from ESAT-STADIUS & UZ Leuven have previously validated this approach using a behind-the-ear (BTE) wEEG device (The Sensor Dot, Byteflies, Antwerpen, Belgium). In a pilot study, an ML algorithm developed by the group achieved 98% sensitivity for detecting absence seizures in a hospital setting compared to standard EEG(6). Furthermore, a subsequent home-based pilot demonstrated the feasibility of using this system for treatment optimization(9).
1.4 Justification for the Current Investigation While the BTE form factor has been validated, it may not be the optimal solution for all patients due to cosmetic concerns, comfort, or lifestyle constraints. To facilitate widespread adoption and personalized care, it is necessary to validate alternative wEEG form factors, such as earEEG.
The device under investigation in this study, the NeuroBuds™, uses a novel ear electrode configuration that lacks rigorous clinical validation against the gold standard for absence seizure detection.
Therefore, the primary purpose of this study is to validate the signal quality and diagnostic accuracy of the ESAT-STADIUS ML algorithms on the signals recorded with the Neurobuds against simultaneous standard vEEG. This validation is a prerequisite for developing a device-agnostic ML algorithm capable of processing data from various manufacturers and electrode montages.
1.5 Benefit/Risk Assessment The IMD is CE-marked, non-invasive, and poses minimal risk to participants, comparable to that of standard scalp EEG electrodes. The potential risks are limited to mild skin irritation or discomfort at the electrode sites. The potential benefit is the validation of a less invasive monitoring alternative. Successful validation may allow for future home-based seizure quantification.
-
Investigation objectives & design
2.1 Investigation objectives
Primary Objective The primary objective of this investigation is to validate the diagnostic accuracy of an investigational ear wEEG device, namely the NeuroBuds (Cebreo Medical), and an ML algorithm in detecting typical absence seizures. Specifically, the study aims to determine the sensitivity, precision, F1-score, and the FAR/24h of the ML seizure detection algorithm applied to signals recorded by the IMD, compared with simultaneous gold-standard video-EEG (vEEG) annotated by a neurologist.
Secondary Objectives
- Signal Quality: To assess the signal quality and artifact susceptibility of novel electrode form factors (earEEG) compared to standard wet scalp electrodes.
- Usability and Comfort: To evaluate patient and caregiver acceptance, comfort, and ease of use of the IMD in both hospital and home environments.
- Home Validation: To demonstrate the robustness of the data collection pipeline and algorithm performance in a real-world home environment, distinct from the controlled hospital setting.
Hypothesis In the hospital setting, the ML algorithm will achieve seizure-detection sensitivity of ≥90% (relative to simultaneous neurologist-annotated vEEG) after analyzing the data obtained with the IMD. These results should be comparable to those previously achieved with the BTE wEEG.
2.2 Primary endpoint
The primary endpoint is the diagnostic performance of the automated absence seizure detection algorithm using the investigational device data, measured by:
- Sensitivity (Recall): The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm.
- Precision: the proportion of positive predictions that were actually correct when compared to the vEEG.
- F1-score: a harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity.
- False Alarm Rate (FAR): The number of false positive detections per 24 hours of recording.
2.3 Secondary endpoints
Signal Quality Metrics: Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG.
Usability Scores: Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort & user experience, and User Perspective Questionnaire).
Data Yield: The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions.
References
- Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1475-1499. doi:10.1111/epi.17236
- Jallon P, Latour P. Epidemiology of Idiopathic Generalized Epilepsies. Epilepsia. 2005;46(s9):10-14. doi:10.1111/j.1528-1167.2005.00309.x
- Caplan R, Siddarth P, Stahl L, et al. Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia. 2008;49(11):1838-1846. doi:10.1111/j.1528-1167.2008.01680.x
- Gruenbaum BF, Sandhu MRS, Bertasi RAO, et al. Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia. 2021;62(5):1041-1056. doi:10.1111/epi.16862
- Callenbach PMC, Bouma PAD, Geerts AT, et al. Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res. 2009;83(2-3):249-256. doi:10.1016/j.eplepsyres.2008.11.011
- Swinnen L, Chatzichristos C, Jansen K, et al. Accurate detection of typical absence seizures in adults and children using a two-channel electroencephalographic wearable behind the ears. Epilepsia. 2021;62(11):2741-2752. doi:10.1111/epi.17061
- Pizarro J, O'Sullivan S, Walker MC. How accurately do adult patients report their absence seizures? Epilepsia Open. Published online March 28, 2023:epi4.12689. doi:10.1002/epi4.12689
- Baud MO, Kleen JK, Mirro EA, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat Commun. 2018;9(1):88. doi:10.1038/s41467-017-02577-y
- Macea J, Chatzichristos C, Bhagubai M, De Vos M, Van Paesschen W. Tailoring antiseizure treatment with a wearable device: A proof-of-concept study in absence epilepsy. Epilepsia. 2025;66(7):2295-2306. doi:10.1111/epi.18384
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Jaiver Macea
- Telefonní číslo: +3216348273
- E-mail: jaiver.macea@uzleuven.be
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adults and children with idiopathic generalized epilepsy syndromes and typical absence seizures.
Popis
Inclusion Criteria:
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
- At least 18 years of age at the time of signing the ICF or at least 6 years of age at the time their parents/legal representatives sign the caregiver's IFC and the minor participants sign the age-appropriate IFC.
- Confirmed diagnosis of the following idiopathic generalized epilepsy syndromes: CAE, JAE, or JME.
- Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some Intra-Uterine Devices (IUDs), true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the investigation treatment(s)) or commitment to a vasectomised partner.
- Language: Subject and/or legal guardian must be able to understand the study instructions and the Informed Consent documents. These will be available in English and Dutch.
Exclusion Criteria:
- Patient has a history of other generalized epilepsy syndromes, such as Lennox-Gastaut.
- Anatomical Constraints: Anatomical abnormalities of the outer ear or ear canal that prevent the proper fit of the earEEG device.
- Participation in another clinical trial with an investigational drug or device that would interfere with the endpoints of this study.
- Female who is pregnant, breastfeeding, or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: CASE_ONLY
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
|---|
|
Absence patients
Adults and children with idiopathic generalized epilepsy syndromes, i.e., Childhood Absence Epilepsy, Juvenile Absence Epilepsy, and Juvenile Myoclonic Epilepsy, with active disease and having typical absences. Prospective, single-center, open-label, comparative diagnostic accuracy study. Study participants will be contacted during the screening phase based on the scheduled admission for 24-hour vEEG in the epilepsy monitoring units of UZ Leuven. After screening and signing the IFC, they will be asked to come to the hospital for ear-mold imprinting. These prints will serve as the basis for customizing the headset. The study will employ a hybrid design, consisting of two phases: Phase A (In-Hospital Validation: participants will wear the IMD simultaneously with the standard 10-20 scalp EEG montage. This provides the ground truth labels for validation. Phase B (At home): participants will wear the device at least once a week for 3 weeks to assess real-world usability |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sensitivity (Recall)
Časové okno: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
The proportion of true absence seizures (defined as 3Hz Spike and Wave Discharges ≥ 3 seconds identified on the gold-standard vEEG) that are correctly detected by the wEEG algorithm. |
1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
|
Precision
Časové okno: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
The proportion of positive predictions that were actually correct when compared to the vEEG. |
1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
|
F1-score
Časové okno: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
The harmonic mean metric used to evaluate the overall performance of the ML model. It uses both precision and sensitivity. |
1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
|
False Alarm Rate in 24 hours
Časové okno: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
The number of false positive detections per 24 hours of recording. |
1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Signal quality
Časové okno: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
Comparative hourly analysis of root mean square (RMS) and signal-to-noise ratio in the alpha band (SNR-Alpha) in the signals originated with the IMD channels and the spatially corresponding channels of the standard 10-20 EEG. |
1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
|
|
Usability Scores
Časové okno: 3 weeks, when the IMD will be used during 24 hours continuously at least once a week.
|
Quantitative assessment of user experience (patients/caregivers) using standardized questionnaires (i.e., System Usability Scale, final questionnaire-comfort & user experience, and User Perspective Questionnaire). |
3 weeks, when the IMD will be used during 24 hours continuously at least once a week.
|
|
Data Yield
Časové okno: 3 weeks, when the IMD will be used during 24 hours continuously at least once a week.
|
The percentage of interpretable (artifact-free) data obtained during unsupervised home recording sessions. |
3 weeks, when the IMD will be used during 24 hours continuously at least once a week.
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Lauranne Scheldeman, UZ Leuven
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- S72895
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.
Časový rámec sdílení IPD
Two years after the analysis, we will post the database, along with all measurements and code, on OpenNeuro.
Kritéria přístupu pro sdílení IPD
It will be open access
Typ podpůrných informací pro sdílení IPD
- ANALYTIC_CODE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .